Literature DB >> 7767645

Therapeutic antisense and ribozymes.

J J Rossi1.   

Abstract

The regulation of expression of genetic information by complementary pairing of sense and antisense nucleic acid strands has been termed 'antisense', and is a mechanism used throughout nature to regulate gene expression. It is now possible to design antisense DNA oligonucleotides, or catalytic antisense RNAs (ribozymes) which can pair with and functionally inhibit the expression of any single stranded nucleic acid in a sequence specific fashion. This high degree of specificity has made them attractive candidates for therapeutic agents. These molecules have the potential for the treatment of a wide variety of diseases. The recent development of retroviral as well as other viral and non-viral based delivery schemes make the clinical use of these molecules a virtual certainty.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767645     DOI: 10.1093/oxfordjournals.bmb.a072948

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  6 in total

Review 1.  Small nucleolar RNAs: versatile trans-acting molecules of ancient evolutionary origin.

Authors:  Michael P Terns; Rebecca M Terns
Journal:  Gene Expr       Date:  2002

2.  Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA.

Authors:  T Kozu; E Sueoka; S Okabe; N Sueoka; A Komori; H Fujiki
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Targeted tumor killing via an intracellular antibody against erbB-2.

Authors:  J Deshane; G P Siegal; R D Alvarez; M H Wang; M Feng; G Cabrera; T Liu; M Kay; D T Curiel
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

4.  Expression of an antisense hla fragment in Staphylococcus aureus reduces alpha-toxin production in vitro and attenuates lethal activity in a murine model.

Authors:  D S Kernodle; R K Voladri; B E Menzies; C C Hager; K M Edwards
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

Review 5.  Prospects for genetic intervention in primary open-angle glaucoma.

Authors:  M K Wirtz; T S Acott; J R Samples; J C Morrison
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

6.  Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.

Authors:  G Hartmann; A Krug; K Waller-Fontaine; S Endres
Journal:  Mol Med       Date:  1996-07       Impact factor: 6.354

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.